{"id":20258,"date":"2011-09-28T02:51:11","date_gmt":"2011-09-28T06:51:11","guid":{"rendered":"http:\/\/asweetlife.org\/?p=20258"},"modified":"2015-12-30T03:26:45","modified_gmt":"2015-12-30T08:26:45","slug":"biodels-ultra-rapid-insulin-fails-in-second-phase-1-trial","status":"publish","type":"post","link":"https:\/\/asweetlife.org\/?p=20258","title":{"rendered":"Biodel&#8217;s Ultra Rapid Insulin Fails in Second Phase 1 Trial"},"content":{"rendered":"<div>\n<div style=\"text-align: justify;\"><a href=\"https:\/\/asweetlife.org\/wp-content\/uploads\/2011\/09\/biodel_logo.png\" rel=\"mfp\"><img decoding=\"async\" class=\"alignleft size-full wp-image-20260 lazyload\" title=\"biodel_logo\" src=\"data:image\/gif;base64,R0lGODlhAQABAAAAACH5BAEKAAEALAAAAAABAAEAAAICTAEAOw==\" data-src=\"https:\/\/asweetlife.org\/wp-content\/uploads\/2011\/09\/biodel_logo.png\" alt=\"\" width=\"175\" height=\"75\" \/><\/a>Biodel&#8217;s\u00a0ultra-rapid-acting formulations of recombinant human insulin,\u00a0BIOD-105 and BIOD-107, failed to meet\u00a0the company&#8217;s target product profile in the second phase 1 clinical trial\u00a0at\u00a0Oregon Health and Sciences University and will therefore not be advancing to phase 2 trials. \u00a0The\u00a0top-line results from the phase 1 clinical trial of BIOD-105 and BIOD-107 was meant to\u00a0evaluate the pharmacokinetic, pharmacodynamic and infusion site tolerability profiles of these ultra-rapid-acting formulations of recombinant human insulin, relative to Humalog,<sup>\u00a0<\/sup>when delivered by insulin pumps. \u00a0 \u00a0<\/div>\n<\/div>\n<div>\n<div style=\"text-align: justify;\">\n<div>\n<div>\u00a0<\/div>\n<div>The trial was a single-center, randomized, double-blind, three-period crossover trial in 8 subjects with type 1 diabetes. Each study drug was administered on separate days. \u00a0Pharmacodynamics were assessed using the euglycemic clamp method. \u00a0Local infusion site discomfort was measured with a 100 mm visual analog scale and patient questionnaires. \u00a0<\/div>\n<div>\u00a0<\/div>\n<div>In this study, BIOD-105 and BIOD-107 demonstrated slightly more rapid absorption (as reflected by the mean time to 50% maximal insulin concentration), and markedly slower declines from peak effect than Humalog with no significant differences among the three drugs regarding infusion site toleration.\u00a0<\/div>\n<div>\u00a0<\/div>\n<\/div>\n<\/div>\n<div style=\"text-align: justify;\">Following these results the company said it would continue its ultra-rapid-acting prandial insulin program of both recombinant human insulin and insulin analogs.\u00a0The company plans to provide an update on product development plans and timelines in the fourth calendar quarter of 2011.\u00a0<\/div>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>Biodel&#8217;s ultra-rapid-acting formulations of recombinant human insulin, BIOD-105 and BIOD-107, failed to meet the company&#8217;s target product profile in the second phase 1 clinical trial at Oregon Health and Sciences University and will therefore not be advancing to phase 2 trials.  The top-line results from the phase&#8230;<\/p>\n","protected":false},"author":131,"featured_media":20260,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_relevanssi_hide_post":"","_relevanssi_hide_content":"","_relevanssi_pin_for_all":"","_relevanssi_pin_keywords":"","_relevanssi_unpin_keywords":"","_relevanssi_related_keywords":"","_relevanssi_related_include_ids":"","_relevanssi_related_exclude_ids":"","_relevanssi_related_no_append":"","_relevanssi_related_not_related":"","_relevanssi_related_posts":"","_relevanssi_noindex_reason":"","footnotes":""},"categories":[1441],"tags":[488,862],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v22.9 (Yoast SEO v22.9) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Biodel&#039;s Ultra Rapid Insulin Fails in Second Phase 1 Trial<\/title>\n<meta name=\"description\" content=\"Biodel&#039;s ultra-rapid-acting formulations of recombinant human insulin failed to meet the company&#039;s target product profile in the second phase 1 clinical trial aand will therefore not be advancing to phase 2 trials.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/asweetlife.org\/?p=20258\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"ASweetLife Team\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/asweetlife.org\/?p=20258\",\"url\":\"https:\/\/asweetlife.org\/?p=20258\",\"name\":\"Biodel's Ultra Rapid Insulin Fails in Second Phase 1 Trial\",\"isPartOf\":{\"@id\":\"https:\/\/asweetlife.org\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/asweetlife.org\/?p=20258#primaryimage\"},\"image\":{\"@id\":\"https:\/\/asweetlife.org\/?p=20258#primaryimage\"},\"thumbnailUrl\":\"https:\/\/asweetlife.org\/wp-content\/uploads\/2011\/09\/biodel_logo.png\",\"datePublished\":\"2011-09-28T06:51:11+00:00\",\"dateModified\":\"2015-12-30T08:26:45+00:00\",\"author\":{\"@id\":\"https:\/\/asweetlife.org\/#\/schema\/person\/5de2b093878b82b0ea97917f8fd72585\"},\"description\":\"Biodel's ultra-rapid-acting formulations of recombinant human insulin failed to meet the company's target product profile in the second phase 1 clinical trial aand will therefore not be advancing to phase 2 trials.\",\"breadcrumb\":{\"@id\":\"https:\/\/asweetlife.org\/?p=20258#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/asweetlife.org\/?p=20258\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/asweetlife.org\/?p=20258#primaryimage\",\"url\":\"https:\/\/asweetlife.org\/wp-content\/uploads\/2011\/09\/biodel_logo.png\",\"contentUrl\":\"https:\/\/asweetlife.org\/wp-content\/uploads\/2011\/09\/biodel_logo.png\",\"width\":175,\"height\":75,\"caption\":\"biodel logo-\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/asweetlife.org\/?p=20258#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/asweetlife.org\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Biodel&#8217;s Ultra Rapid Insulin Fails in Second Phase 1 Trial\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/asweetlife.org\/#website\",\"url\":\"https:\/\/asweetlife.org\/\",\"name\":\"ASweetLife\",\"description\":\"The Diabetes Magazine\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/asweetlife.org\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/asweetlife.org\/#\/schema\/person\/5de2b093878b82b0ea97917f8fd72585\",\"name\":\"ASweetLife Team\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/asweetlife.org\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/ba76b5c6c27d32738b13f9a8a5cfcf02?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/ba76b5c6c27d32738b13f9a8a5cfcf02?s=96&d=mm&r=g\",\"caption\":\"ASweetLife Team\"},\"url\":\"https:\/\/asweetlife.org\/?author=131\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Biodel's Ultra Rapid Insulin Fails in Second Phase 1 Trial","description":"Biodel's ultra-rapid-acting formulations of recombinant human insulin failed to meet the company's target product profile in the second phase 1 clinical trial aand will therefore not be advancing to phase 2 trials.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/asweetlife.org\/?p=20258","twitter_misc":{"Written by":"ASweetLife Team","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/asweetlife.org\/?p=20258","url":"https:\/\/asweetlife.org\/?p=20258","name":"Biodel's Ultra Rapid Insulin Fails in Second Phase 1 Trial","isPartOf":{"@id":"https:\/\/asweetlife.org\/#website"},"primaryImageOfPage":{"@id":"https:\/\/asweetlife.org\/?p=20258#primaryimage"},"image":{"@id":"https:\/\/asweetlife.org\/?p=20258#primaryimage"},"thumbnailUrl":"https:\/\/asweetlife.org\/wp-content\/uploads\/2011\/09\/biodel_logo.png","datePublished":"2011-09-28T06:51:11+00:00","dateModified":"2015-12-30T08:26:45+00:00","author":{"@id":"https:\/\/asweetlife.org\/#\/schema\/person\/5de2b093878b82b0ea97917f8fd72585"},"description":"Biodel's ultra-rapid-acting formulations of recombinant human insulin failed to meet the company's target product profile in the second phase 1 clinical trial aand will therefore not be advancing to phase 2 trials.","breadcrumb":{"@id":"https:\/\/asweetlife.org\/?p=20258#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/asweetlife.org\/?p=20258"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/asweetlife.org\/?p=20258#primaryimage","url":"https:\/\/asweetlife.org\/wp-content\/uploads\/2011\/09\/biodel_logo.png","contentUrl":"https:\/\/asweetlife.org\/wp-content\/uploads\/2011\/09\/biodel_logo.png","width":175,"height":75,"caption":"biodel logo-"},{"@type":"BreadcrumbList","@id":"https:\/\/asweetlife.org\/?p=20258#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/asweetlife.org\/"},{"@type":"ListItem","position":2,"name":"Biodel&#8217;s Ultra Rapid Insulin Fails in Second Phase 1 Trial"}]},{"@type":"WebSite","@id":"https:\/\/asweetlife.org\/#website","url":"https:\/\/asweetlife.org\/","name":"ASweetLife","description":"The Diabetes Magazine","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/asweetlife.org\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/asweetlife.org\/#\/schema\/person\/5de2b093878b82b0ea97917f8fd72585","name":"ASweetLife Team","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/asweetlife.org\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/ba76b5c6c27d32738b13f9a8a5cfcf02?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/ba76b5c6c27d32738b13f9a8a5cfcf02?s=96&d=mm&r=g","caption":"ASweetLife Team"},"url":"https:\/\/asweetlife.org\/?author=131"}]}},"_links":{"self":[{"href":"https:\/\/asweetlife.org\/index.php?rest_route=\/wp\/v2\/posts\/20258"}],"collection":[{"href":"https:\/\/asweetlife.org\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/asweetlife.org\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/asweetlife.org\/index.php?rest_route=\/wp\/v2\/users\/131"}],"replies":[{"embeddable":true,"href":"https:\/\/asweetlife.org\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=20258"}],"version-history":[{"count":0,"href":"https:\/\/asweetlife.org\/index.php?rest_route=\/wp\/v2\/posts\/20258\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/asweetlife.org\/index.php?rest_route=\/wp\/v2\/media\/20260"}],"wp:attachment":[{"href":"https:\/\/asweetlife.org\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=20258"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/asweetlife.org\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=20258"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/asweetlife.org\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=20258"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}